Despite the availability of a highly effective vaccine, barriers to preventing hepatitis B infection in the U.S. remain. These barriers include low rates of hepatitis B vaccination coverage among adults and increased rates of injection drug use – a major risk factor for hepatitis B (HBV), hepatitis C (HCV), and HIV infections – as the opioid epidemic in the U.S. continues.